Thierry Conrozier

InstitutionNord Franche-Comté Hospital
AddressFrance
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 10 Covid-19 publications, with a maximum of 2 publications in June 2020
    All Publications
    Bar chart showing 87 publications over 27 distinct years, with a maximum of 9 publications in 1998
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Klopfenstein T, Gendrin V, Gerazime A, Conrozier T, Balblanc JC, Royer PY, Lohse A, Mezher C, Toko L, Guillochon C, Badie J, Pierron A, Kadiane-Oussou N'J, Puyraveau M, Zayet S. Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia. Infect Dis Ther. 2021 Sep; 10(3):1195-1213. PMID: 34247325.
      Citations: 3     
    2. Klopfenstein T, Gendrin V, Conrozier T, Gerazime A, Puyraveau M, Zayet S. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Ann Rheum Dis. 2021 Jun 23. PMID: 34162593.
      Citations:    Fields:    
    3. Klopfenstein T, Gendrin V, Kadiane-Oussou NJ, Conrozier T, Zayet S. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022 01; 32(1):e2239. PMID: 33882179.
      Citations:    Fields:    
    4. Klopfenstein T, Conrozier T, Kadiane-Oussou NJ, Gendrin V, Zayet S. Is There Still a Place for Tocilizumab in Coronavirus Disease 2019? Open Forum Infect Dis. 2021 Feb; 8(2):ofab013. PMID: 33628858.
      Citations:    
    5. Lohse A, Bossert M, Bozgan AM, Charpentier A, Guillochon C, Bourgoin C, Balblanc JC, Conrozier T. Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study. Clin Exp Rheumatol. 2020 Nov-Dec; 38(6):1273. PMID: 33253100.
      Citations:    Fields:    Translation:HumansPHPublic Health
    6. Zayet S, Klopfenstein T, Mezher C, Gendrin V, Conrozier T, Ben Abdallah Y. Coronavirus disease 2019 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema, France. New Microbes New Infect. 2020 Nov; 38:100785. PMID: 33072337.
      Citations: 4     
    7. Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, Toko L, Royer PY, Balblanc JC, Gendrin V, Conrozier T. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Oct; 99:491-495. PMID: 32798660.
      Citations: 15     Fields:    Translation:HumansCellsPHPublic Health
    8. Conrozier T, Lohse A, Balblanc JC, Dussert P, Royer PY, Bossert M, Bozgan AM, Gendrin V, Charpentier A, Toko L, Badie J, Mezher C, Roux MF, Kadiane-Oussou NJ, Contreras R, Kessler J, Mazurier I, Klopfenstein T, Zayet S. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):742-747. PMID: 32573419.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic Health
    9. Lohse A, Klopfenstein T, Balblanc JC, Royer PY, Bossert M, Gendrin V, Charpentier A, Bozgan AM, Badie J, Bourgoin C, Contreras R, Mazurier I, Conrozier T, Zayet S. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Microbes Infect. 2020 10; 22(9):500-503. PMID: 32574789.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    10. Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, Toko L, Mezher C, Kadiane-Oussou NJ, Bossert M, Bozgan AM, Charpentier A, Roux MF, Contreras R, Mazurier I, Dussert P, Gendrin V, Conrozier T. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020 Aug; 50(5):397-400. PMID: 32387320.
      Citations: 105     Fields:    Translation:HumansCellsPHPublic Health